What is Inhibikase Therapeutics Inc (IKT)?

# 🧾 What This Document Is This is a Form 8-K filing, which companies use to announce major news to investors. This specific announcement shares that Inhibikase Therapeutics has started its most important clinical trial yet—a **Phase 3 study** of their drug **IKT-001** for treating **Pulmonary Arte

Read summaryView on SEC EDGAR

SEC filings

All filings →

1 recent filing shown in the timeline above. View all SEC filings →

Insider trades

All insider trades →

Inhibikase Therapeutics Inc has no reported insider trades in the last 90 days.

Institutional holders

All holders →

As of 2025-12-31 · prior 2025-09-30

Trails Edge Capital Partners, LP$12.7M

6,178,124 sh● NEW

Soleus Capital Management, L.P.$22.3M

10,875,000 sh+71.9%

Siren, L.L.C.$12.0M

5,850,000 sh● NEW

Sands Capital Ventures, LLC$26.7M

13,018,965 sh+18.9%

Squadron Capital Management LLC$8.7M

4,225,000 sh● NEW

ADAR1 Capital Management, LLC$16.5M

8,063,949 sh+53.7%

Saturn V Capital Management LLC$7.9M

3,856,799 sh● NEW

Blackstone Inc.$12.2M

5,938,276 sh+125.1%

People at Inhibikase Therapeutics Inc

Quarterly financials

Full financials →

Revenue trend

03/25

—

NI -$13.7M

06/25

—

NI -$9.9M

09/25

—

NI -$11.9M

RevenueNI = Net Income

EPS trend (diluted)

Latest: $-0.13

Prior: $-0.11

Revenue sparkline